Distraction-induced analgesia is a clinically useful form of pain modulation.
Introduction
Pain is a multidimensional, subjective experience, and its perception requires supraspinal processing. Pain is modulated by cognitive factors, and distraction interventions are frequently used to relieve pain. Distraction results in withdrawal of attention from the noxious stimulus/input and reduced pain perception (Eccleston and Crombez, 1999; Wismeijer and Vingerhoets, 2005) . Various distraction techniques, from simple mathematical tasks to sophisticated virtual-reality devices, have been used clinically to reduce pain (Hoffman et al., 2000; Maclaren and Cohen, 2007) . Distraction has also been shown to reduce the perceived intensity of experimental pain in humans in laboratory settings (Bantick et al., 2002; Villemure and Bushnell, 2002) .
The neural mechanisms underlying distraction-induced analgesia are poorly understood. Human brain imaging studies suggest involvement of brain regions associated with attention, affect, and endogenous analgesia (Petrovic and Ingvar, 2002; Valet et al., 2004) . Evidence suggests a key role for the endogenous cannabinoid (endocannabinoid; EC) system in fear/stress-induced analgesia (Butler and Finn, 2009; and in the placebo response (Benedetti et al., 2011) . The main constituents of the EC system are two endogenous ligands, N-arachidonoyl ethanolamide (anandamide; AEA) and 2-arachidonoylglycerol (2-AG) and two Gi/o-protein coupled receptors, cannabinoid1 (CB1) and cannabinoid2 (CB2) (Di Marzo, 2008 ). The EC system also regulates selective and sustained attention in humans and animals (Arguello and Jentsch, 2004; Solowij et al., 1995) . In rodents, cannabinoid receptor agonists WIN55212-2 (Arguello and Jentsch, 2004; Pattij et al., 2007) , AEA (Panlilio et al., 2009 ) and ∆ 9 -THC (Verrico et al., 2004) impaired attentional performance in operant reactiontime tasks, while the CB1 receptor antagonist/inverse agonist rimonabant enhanced attentional 5 responding (Pattij et al., 2007) . Conditional CB1 mutant mice also showed reduced attention towards an unfamiliar object (Lafenetre et al., 2009 ). The hippocampus is activated by noxious stimuli in humans and rodents (Apkarian et al., 2005; Shih et al., 2008) and plays a role in cognitive modulation of pain; specifically, it is activated during exacerbation of pain by expectation (Ploghaus et al., 2001) . The ventral hippocampus (vHip) is anatomically connected to the amygdala and prefrontal cortex (Ishikawa and Nakamura, 2006; Pitkanen et al., 2000) , regions critically involved in attention/distraction and descending control of pain. Amygdalar and prefrontal cortical neurons project to the periaqueductal grey (Floyd et al., 2000; Rizvi et al., 1991) , forming an integral part of the descending inhibitory pain pathway. Components of the EC system are highly expressed in the hippocampus (Felder et al., 1996; Freund et al., 2003) . A recent study from our laboratory demonstrated that the vHip EC system plays an important role in expression of fear-conditioned analgesia in rats (Ford et al., 2011) . We hypothesised that it may, therefore, be relevant to distraction-induced analgesia also.
We previously established and validated a rat model of distraction-induced analgesia whereby exposure to a non-aversive distractor suppressed formalin-evoked nociceptive behaviour . The present study aimed to investigate the effects of systemic administration of the CB1 receptor antagonist/inverse agonist, rimonabant, on distraction-induced antinociception (DIA) in this rat model, and to determine whether DIA was associated with alterations in EC concentrations in the vHip. 6
Materials and Methods

Animals
Male Lister-hooded rats (260-300 g on the day of testing; Charles River, UK) were housed in groups of three in plastic-bottomed cages (45 cm x 25 cm x 20 cm) containing wood shavings as bedding. The animals were maintained at a constant temperature (21 ± 2° C) under standard lighting conditions (12 h:12 h light:dark cycle, lights on from 07:00 h to 19:00 h). Food and water were available ad libitum. The experimental protocol was carried out in accordance with the guidelines and approval of the Animal Care and Research Ethics Committee, National University of Ireland, Galway under license from the Irish Department of Health and Children and in compliance with the European Communities Council directive 86/609, and all efforts were made to minimise the number of animals used and their suffering.
Chemicals and Drug preparation
The CB1 receptor antagonist/inverse agonist rimonabant (SR141716A) [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1-H-pyrazole-3-carboxamide, NIMH Chemical Synthesis Programme: Batch no. 10937-163-1] (1 mg/kg) was prepared fresh on the day of use, and dissolved in a vehicle of ethanol:cremaphor:saline (1:1:18) (Sigma, Ireland).
The dose and time of administration was based on previous research demonstrating rimonabant-induced attenuation of fear-induced analgesia (Finn et al., 2004) . The drug or vehicle was administered at a volume of 2 ml/kg via the intraperitoneal (i.p.) route. Formalin (Sigma-Aldrich, Ireland) was also prepared fresh on the day of use from 37% formaldehyde to give a final concentration of 2.5% in 0.9% saline, and 50µl was administered by intraplantar injection to the right hind paw. N-arachidonyl ethanolamide (AEA) and 2-arachidonylglycerol (2AG) and their corresponding synthetic deuterated internal standards (N-arachidonyl ethanolamide-d8 (AEA-d8) and 2-arachidonylglycerol-d8 (2AG-d8)) were purchased from Cayman Europe (Tallinn, Estonia). Acetonitrile and formic acid were obtained from Lennox Laboratory Supplies (Dublin, Ireland). All solvents and chemicals were of HPLC grade or higher.
Apparatus
Habituation and testing took place in a specially constructed arena (30 cm x 30 cm x 40 cm) as described previously and as shown in Figure 1 . The arena floor was made of Perspex and the three remaining walls of each chamber were white, constructed from wood.
The light intensity illuminating the arena was maintained at 200 lux. A bat detector (Batbox Duet, UK) was placed next to the arena to detect ultrasonic vocalization in the 22 kHz range, and a video camera was positioned under the arena. Live video images and audio signals were recorded onto DVD for subsequent analysis. Identical to that used previously , the novel object was an inverted plastic falcon tube filled with sand, attached to the base of the arena using Velcro®; the object could be explored freely but could not be displaced by the rat. To remove olfactory cues, the arena was cleaned and wiped down with 0.5% acetic acid solution pre-and post-habituation and testing of each rat; the novel object was also wiped down with acetic acid solution between trials.
Experimental Procedure
Subjects were randomly assigned to one of four groups (n = 9-11/group), and the sequence of habituation and testing was randomized throughout the experiment in order to minimise any confounding effects associated with the order of testing. Experiments were conducted between 08:30 h and 15:00 h. Subjects in all treatment groups were habituated to the arena for 10 minutes each day for seven days prior to experimentation. On the day of testing, all rats received an intraplantar injection of 50 µl formalin (2.5% in 0.9% saline) into the right hind paw under brief isoflurane anaesthesia, immediately followed by an i.p injection of rimonabant
(1 mg/kg) or vehicle in an injection volume of 2 ml/kg. Rats were returned to their home cage for 30 minutes and were then placed back into the same arena to which they had been habituated for the previous days. The arena contained either no distracting stimulus (control) or the novel object (as described above) placed in the centre of the arena. Behaviour was then scored for a 30-minute period, 30-60 minutes post-formalin and post-i.p. drug injection, since our previous work has shown that this period of the second phase formalin response is subject to attentional modulation in this DIA paradigm . Immediately after the trial, rats were killed by decapitation. Brains were removed quickly, snap-frozen on dry ice, and stored at -80°C.
The experimental groups were: no-object + formalin + vehicle (No Object-Vehicle; n = 10), no-object + formalin + rimonabant (No Object-Rimonabant; n = 9), object + formalin + vehicle (Object-Vehicle; n = 11) and object + formalin + rimonabant (Object-Rimonabant; n = 10).
Behavioural analysis
Behaviour during the 30-minute trial was analysed with the aid of Ethovision ® behavioural tracking software (Noldus, Wageningen, The Netherlands). Formalin-evoked nociceptive behaviour was scored as time spent licking, biting or flinching the injected paw. Locomotor activity was assessed by tracking the distance moved by the rat. Directed attention towards the novel object and general, non-object directed behaviour (a composite duration of sniffing + rearing + grooming + walking) were also scored over the experimental period. Directed attention was defined and scored as the duration of time during which the rat's head was directed towards the object and within a 2 cm annulus surrounding it, touching the object with the nose or forepaws, or rearing against the object. Formalin-induced oedema was assessed as the difference between the post-mortem diameter of the right hind paw and the diameter before formalin administration measured using Vernier callipers. The number of faecal pellets was also recorded at the end of the 30-minute trial period.
Measurement of endocannabinoids from Palkovits punched tissue using liquid chromatography-tandem mass spectrometry (LC-MS-MS)
To determine the effect of exposure to the novel object distractor on endocannabinoid concentrations, frozen brain sections were cut (300 µm thickness) on a cryostat from Object-Vehicle and No Object-Vehicle group rats; the vHip was isolated from frozen sections using a cylindrical brain punch (Harvard Apparatus, internal diameter 2.0mm) and stored at -80 o C prior to extraction for LC-MS-MS as described previously (Ford et al., 2011; Olango et al., 2012; Rea et al., 2013) . The length of tissue punched was approximately 1.6 mm (start: bregma -4.3 mm) (Paxinos and Watson, 1998) 
Results
Effects of rimonabant on DIA
Intraplantar injection of formalin produced robust licking, biting and flinching of the injected paw. There was a significant time x drug interaction (F(2.72) = 3.32, p<0.05) and the drug x object interaction approached the level of statistical significance (F(1, 36) =3.86, p=0.057). As there was no effect of time, data at each time point were analysed by a one-way ANOVA followed by Fisher's LSD post hoc tests. Rats exposed to the novel object distractor displayed significantly less formalin-evoked nociceptive behaviour in the first 10 minutes of the trial compared with rats not exposed to the object (Figure 2 
Effects of rimonabant on attention directed at the novel object in the presence of formalinevoked nociceptive tone
A significant negative correlation between duration of directed attention and formalin-evoked nociceptive behaviour was observed in formalin-treated rats exposed to novel object distractor (vehicle-and rimonabant-treated) during the first 10 minutes of the trial (r 2 = 0.43, **p<0.01; Figure 3A ). However, there was no significant effect of rimonabant administration on attention directed towards the novel object in the first 10 minutes of the trial ( Figure 3B ).
Effects of rimonabant and novel object distractor on exploratory and fear-related behaviours
Non-object directed behaviour and locomotor activity were not significantly different between groups in the first 10 minutes of the trial (Figure 4A, 4B ). Formalin injection resulted in an increase in paw diameter which was similar in all treatment groups ( Figure 4C ). There was a significant main effect of drug (F(1, 36)=5.66, p<0.05) on the number of faecal pellets produced over the 30 min trial, and the object x drug interaction was close to the level of statistical significance (F(1, 36)=3.57, p=0.067). Post hoc tests showed that the number of faecal pellets produced over the 30-minute trial was unaltered by drug treatment in rats not exposed to the distractor. However, in rats exposed to object, the number of defecations was reduced compared with animals not exposed to the object (No Object-Vehicle vs Object-Vehicle; *p<0.05), an effect that was attenuated by rimonabant administration (Object-Rimonabant vs.
Object-Vehicle ## p<0.01). No specific fear-related behaviours (freezing or 22 kHz ultrasonic vocalisations) were detected in rats from any of the experimental groups (data not shown),
suggesting that rats did not express neophobic behaviours in the arena or during exposure to the novel object.
Effect of novel object exposure on EC levels in the vHip
Exposure of vehicle-treated rats to the novel object was associated with significant elevations in tissue levels of AEA (No Object-Vehicle vs. Object-Vehicle; t(1, 18) = 4.01; ***p<0.001 Figure 5A ) and 2-AG (No Object-Vehicle vs. Object-Vehicle; t(1, 19) = 3.02; **p<0.01 Figure   5B ) in the vHip. Thus, the expression of DIA was accompanied by elevations in EC levels in the vHip.
Discussion
Exposure to a novel object significantly reduced formalin-evoked nociceptive behaviour in rats in agreement with our previous findings . This expression of DIA was associated with increased AEA and 2-AG concentrations in the vHip. The CB1 receptor antagonist/inverse agonist rimonabant prevented DIA, suggesting that this is a CB1 receptormediated phenomenon. These data constitute the first evidence from an animal model for a neurochemical-and receptor-mediated basis for DIA, and suggest that the EC system may be an important neural substrate subserving attentional modulation of pain.
The results of the present study corroborate those of our earlier study demonstrating that exposure to a neutral, non-aversive novel object results in a robust reduction in formalinevoked nociceptive behaviour . Consistent with the original description of the model , overt aversive behaviours (such as avoidance of the unfamiliar object, or fear-related behaviours) were not observed, suggesting that the reduction in nociceptive behaviour in these animals is not related to aversion . Indeed, the reduction in defecation in animals exposed to the novel object may be indicative of reduced emotionality in these rats, an effect that was attenuated by rimonabant. One minor difference between the studies is that observed significant effects on both formalinevoked elevation and licking/biting/flinching of the injected hind paw (expressed as a composite pain score) while in the present study we report effects on the latter pain-related behaviour only. Minor methodological differences between the two studies, such as the inclusion of i.p. injection in the present study, may account for this discrepancy. Overall, however, the DIA model originally described by appears to be robust and reproducible.
Our results demonstrate that DIA was completely reversed by the CB1 receptor antagonist/inverse agonist rimonabant during the first 10 minutes of the trial. We chose rimonabant because this compound, at the same dose as that used in the present study, has been shown to attenuate suppression of pain by an aversive stimulus (Finn et al., 2004) . Taken together, these findings suggest that the endocannabinoid system mediates antinociception induced by non-aversive stimuli in addition to its well-described role in fear/stress-induced analgesia. The attenuation of DIA during the first 10 minutes of the trial only, reflects the fact that this was the period when a statistically significant object-induced reduction in formalinevoked nociceptive behaviour was observed. Rimonabant had no effect on formalin-evoked nociception in rats not exposed to the novel object, indicating a specific effect on DIA rather than a non-specific effect on nociceptive behaviour per se. This finding suggests that the CB1 receptor may not be directly involved in the tonic regulation of formalin-induced pain, which is supported by some previous studies (Beaulieu et al., 2000; Costa et al., 2005; Finn et al., 2004) but is in contrast with others (Calignano et al., 1998; Strangman et al., 1998) . The discrepancies in the literature most likely relate to methodological differences in species or strain, dose, and time or route of drug administration. However, the study by Finn et al. (Finn et al., 2004) was the most similar in design to the present experiment, and also reported no effects of the same dose of rimonabant on formalin-evoked nociceptive behaviour in Listerhooded rats. In the present study, a different dose or route of administration of rimonabant may have had an effect on formalin-evoked nociceptive behaviour in rats not exposed to the object.
However, such a result would then complicate and potentially confound interpretation of the effects of rimonabant in rats exposed to the novel object. For this reason, the dose of rimonabant administered in the present study was chosen to selectively block CB1 receptors without having overt effects on formalin-evoked nociceptive behaviour per se. Neither rimonabant nor exposure to the novel object had any effect on non-object directed behaviour or locomotor activity in the present study, suggesting that the effects of object exposure on formalin-evoked nociceptive behaviour, and the effects of rimonabant thereon, are not due to overt, non-specific effects on behaviour, but instead likely represent specific effects on nociceptive processing.
Attention directed at the novel object was negatively correlated with the duration of this objectdirected attention and the duration of nociceptive behaviour. Thus, rats exhibiting more attention directed at the novel object expressed less formalin-evoked nociceptive behaviour.
These data support human studies demonstrating that cognitive distraction tasks reduce the perceived intensity and unpleasantness of experimental pain (Bantick et al., 2002; Bushnell et al., 2013; Valet et al., 2004; Villemure and Bushnell, 2002) . Intriguingly, rimonabant did not have any significant effect on attention directed at the novel object, despite its effects in blocking DIA. Directed attention was defined as the duration of time during which the rat's head was directed towards the object and within a 2 cm annulus surrounding it, touching the object with the nose or forepaws, or rearing against the object. Thus, it appears that rimonabant blocks DIA via a mechanism which is independent of any direct effects on (a) these measures of directed attention or (b) general locomotor activity. It is likely, therefore, that rimonabant blocks DIA not through an action in brain sites regulating the motor components of attention but rather at sites which subserve non-motor aspects of attention and/or modulation of painrelated behaviour.
Given the role of the vHip in endocannabinoid-mediated fear-induced analgesia (Ford et al., 2011) and its role in differential modulation of fear responding by endocannabinoids in the presence of persistent pain state (Rea et al., 2014) , we investigated whether DIA was associated with alterations in levels of endocannabinoids in this region. Our results indicate that object exposure was associated with marked increases in the levels of AEA and 2-AG in the vHip.
These elevations in levels of AEA and 2-AG in the vHip, coupled with the rimonabant-induced attenuation of DIA, support the hypothesis that endocannabinoids may act at CB1 receptors in the vHip to mediate DIA and provide a solid framework upon which to design future studies to test this hypothesis. Studies have demonstrated robust projections from the ventral hippocampus to the ventral medial prefrontal cortex (PFC), including the medial orbital area, the infralimbic area and the prelimbic areas, which subserve higher order functions including selective attention (Vertes 2006) . Furthermore, the vHip input to the PFC converges with dopaminergic and serotonergic signalling pathways (Azmitia and Segal 1978; Gasbarri et al., 1994) , which are known to exert a powerful modulatory influence over attentional behaviour (Robbins 2000) . Lesions to the vHip have been shown to reduce response accuracy in the attention-demanding 5-choice serial reaction time task (Abela et al., 2013) . A direct connection has also been demonstrated between the ventral CA1 region of the hippocampus and the amygdala (van Groen and Wyss 1990). The central nucleus of the amygdala is involved in control of attentional aspects of stimulus processing, and lesions to this region are associated with impaired visuospatial attention in a continuous-performance task (Holland et al., 2000) .
It is also possible that the vHip, being part of the cortico-limbic system, is capable of modulating the activity of brain regions classically associated with the descending inhibitory pain pathway, including the PFC, amygdala, periaqueductal grey and rostroventromedial medulla, which mediate top-down endogenous modulation of pain. This hypothesis is supported by the presence of reciprocal connections between the vHip and the PFC and amygdala (Ishikawa and Nakamura, 2006; Pikkarainen et al., 1999; Pitkanen et al., 2000; Thierry et al., 2000) . In human brain imaging studies, activity in the PFC (including the anterior cingulate cortex) is increased during DIA (Bantick et al., 2002; Petrovic et al., 2000; Valet et al., 2004) . Moreover, vHip neurons contain cannabinoid, opioid and GABAergic receptors, and intrahippocampal microinjection of morphine produces antinociception mediated by the descending inhibitory pain pathway (Blasco-Ibanez et al., 1998; Favaroni Mendes and Menescal-de-Oliveira, 2008) . Therefore, distraction-related alterations in EC signalling within the vHip could modulate nociceptive transmission through afferent projections to regions comprising the descending inhibitory pain pathway. Further studies are warranted to test this theory.
In conclusion, the present study has confirmed that exposure of rats to a novel object transiently reduces second-phase formalin-evoked nociceptive behaviour and represents a useful model of distraction-induced analgesia. Furthermore, we have demonstrated, for the first time, involvement of the EC system in DIA. The behavioural expression of DIA was attenuated by the CB1 antagonist/inverse agonist rimonabant and was accompanied by increases in the levels of AEA and 2-AG in the vHip. The results offer the first insight into the neurochemical and receptor mechanisms that mediate DIA and provide a framework for the design of future studies aimed at further elucidation of the molecular mechanisms and circuitry that subserve attentional modulation of pain. In the last 10 min of the trial, there was a trend for rimonabant to reduce nociceptive behaviour in rats not exposed to the novel object, but this failed to reach statistical significance (p=0.06). Data are expressed as mean ± SEM, n=9-11/group. Rimonabant did not significantly alter the duration of attention in the first 10 min of the trial.
Figure Legends
Data are expressed as mean ± SEM, n = 10-11. the vehicle-treated rats exposed to the novel object than in vehicle-treated rats not exposed to the object (*p<0.05 Object-Vehicle vs. No Object-Vehicle). This reduction was prevented by administration of rimonabant in the object-exposed rats ( ## p<0.01 Object-Rimonabant vs.
Object-Vehicle). 
